Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Total Valuation
Adaptimmune Therapeutics has a market cap or net worth of $67.90M. The enterprise value is $60.48M.
Market Cap$67.90M
Enterprise Value$60.48M
Share Statistics
Adaptimmune Therapeutics has 263,696,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding263,696,040
Owned by Insiders47.53%
Owned by Institutions0.09%
Financial Efficiency
Adaptimmune Therapeutics’s return on equity (ROE) is -5.98 and return on invested capital (ROIC) is -38.90%.
Return on Equity (ROE)-5.98
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-38.90%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee351.84K
Profits Per Employee-139.95K
Employee Count506
Asset Turnover0.72
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of Adaptimmune Therapeutics is -1.92. Adaptimmune Therapeutics’s PEG ratio is 0.04.
PE Ratio-1.92
PS Ratio0.43
PB Ratio11.47
Price to Fair Value11.47
Price to FCF-1.86
Price to Operating Cash Flow-1.86
PEG Ratio0.04
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.05.
Revenue178.03M
Gross Profit177.96M
Operating Income-68.76M
Pretax Income-67.24M
Net Income-70.81M
EBITDA-52.66M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -73.20M and capital expenditures -2.72M, giving a free cash flow of -75.92M billion.
Operating Cash Flow-73.20M
Free Cash Flow-75.92M
Free Cash Flow per Share-0.29
Dividends & Yields
Adaptimmune Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change-77.39%
50-Day Moving Average0.38
200-Day Moving Average0.74
Relative Strength Index (RSI)43.25
Average Volume (3m)2.43M
Important Dates
Adaptimmune Therapeutics upcoming earnings date is May 15, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 15, 2025
Ex-Dividend Date―
Financial Position
Adaptimmune Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 626.29%
Current Ratio2.92
Quick Ratio2.80
Debt to Market Cap0.18
Net Debt to EBITDA1.28
Interest Coverage Ratio-20.54
Taxes
In the past 12 months, Adaptimmune Therapeutics has paid 3.58M in taxes.
Income Tax3.58M
Effective Tax Rate-0.05
Enterprise Valuation
Adaptimmune Therapeutics EV to EBITDA ratio is -14.21, with an EV/FCF ratio of -10.22.
EV to Sales4.20
EV to EBITDA-14.21
EV to Free Cash Flow-10.22
EV to Operating Cash Flow-10.22
Balance Sheet
Adaptimmune Therapeutics has $151.60M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$77.40M billion.
Cash & Marketable Securities$151.60M
Total Debt$0.00
Net Cash-$77.40M
Net Cash Per Share-$0.29
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 96.95%, with operating margin of -38.62%, and net profit margin of -39.78%.
Gross Margin96.95%
Operating Margin-38.62%
Pretax Margin-37.77%
Net Profit Margin-39.78%
EBITDA Margin-29.58%
EBIT Margin-35.89%
Analyst Forecast
The average price target for Adaptimmune Therapeutics is $1.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.78
Price Target Upside584.62% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast194.23%
EPS Growth Forecast45.50%